| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Ginkgo Bioworks Holdings, Inc.
$6.76
-0.03 (-0.44%)
Market Cap
374.39 M
EPS
-4.32
P/E Ratio
-
Value Trade
10.45 M
-2.3 %
Week
-9.59 %
1 Month
-15.13 %
3 Month
6.09 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
159.28 K
52 Week Range
5.37 - 17.58
% held by Insiders
24.12 %
% held by Institutions
58.7 %
Enterprise Value
205.70 M
Total Shares
55.38 M
Short %
13.19 %
Float Shares
42.42 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ginkgo Bioworks Holdings, Inc.
65Total events
3Upcoming
15Tier-1 (high impact)
2023 – 2026Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
◆AcquisitionCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DNA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DNA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-05-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-05-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-05-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-DNA
Sep 10, 2026▼ -0.4%today
Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines
Ginkgo Bioworks has secured a subcontract worth up to $17.5 million from ARPA-H's GIVE program. This initiative focuses on developing a continuous-flow manufacturing system for RNA medicines. Ginkgo will collaborate with Waterfall Scientific to advance this transformative project, which aims to improve individualized medicine production.
Read more →-DNA
May 7, 2026Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Ginkgo Bioworks reported its first quarter financial results for 2026, showing a significant revenue decline of 49% year-over-year, attributed to the divestiture of its Biosecurity business and ongoing restructuring. The company aims to expand its autonomous lab, Nebula, which is positioned at the forefront of scientific innovation. Despite the challenges, Ginkgo maintains a strong cash position of $373 million.
Read more →-DNA
Apr 30, 2026▲ +12.8%on this news· ran to +29% by day 3
Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation
Ginkgo Bioworks has announced a presentation and Q&A session scheduled for May 7, 2026, to discuss its business performance for the first quarter of 2026. The event will begin at 4:30 p.m. ET, and details will be available on the company's investor relations website. Investors can submit questions in advance via social media or email.
Read more →-DNA
Feb 26, 2026Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business Ginkgo provides an update on its fourth quart
Ginkgo Bioworks has announced its financial results for Q4 and FY 2025, highlighting a 25% decline in total revenues year-over-year. The company reported a net loss of $(313) million for the year, although this was an improvement from the previous year's $(547) million loss. Ginkgo is shifting its focus towards autonomous labs and has agreed to divest its non-core biosecurity business, which will allow for greater investment in its autonomous lab offerings. The company remains in a strong cash position, ending 2025 with $423 million.
Read more →-DNA
Nov 6, 2025Ginkgo Bioworks Reports Third Quarter 2025 Financial Results Ginkgo provides an update on its third quarter financial results
Ginkgo Bioworks announced its financial results for the third quarter of 2025, revealing a substantial decline in revenues compared to the previous year. Total revenue was reported at $39 million, down 56%, with a notable decrease in Cell Engineering and Biosecurity segments. The company's net loss increased to $(81) million, largely due to a prior year non-cash revenue adjustment. Despite these setbacks, Ginkgo maintains a positive outlook for the year, reaffirming its revenue targets and highlighting strategic partnerships that could bolster its position in advancing biotechnology.
Read more →-DNA
Aug 7, 2025Ginkgo Bioworks Reports Second Quarter 2025 Financial Results Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets
Ginkgo Bioworks announced its financial results for the second quarter of 2025, reporting a total revenue of $50 million, a decrease from $56 million in the previous year. Despite the drop in total revenue, the company saw an 8% increase in Cell Engineering revenue primarily driven by demand from biopharma and government sectors. Ginkgo successfully achieved its $250 million cost reduction target ahead of schedule, reflecting operational efficiencies. However, the Biosecurity revenue fell significantly, indicating challenges in that segment of the business.
Read more →-DNA
May 21, 2025▼ -7.4%on this news
Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer
Ginkgo Bioworks announced the appointment of Steven Coen as Chief Financial Officer following Mark Dmytruk's resignation. Coen, who joined Ginkgo as Chief Accounting Officer in 2023, brings over 30 years of financial experience from various industries. His promotion aims to ensure continuity in the financial leadership of the company as it strives for cost reductions and aims for Adjusted EBITDA breakeven by the end of 2026.
Read more →-DNA
May 6, 2025▼ -6.8%on this news
Ginkgo Bioworks Reports First Quarter 2025 Financial Results Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 millio
Ginkgo Bioworks has reported its Q1 2025 financial results, revealing a total revenue of $48 million, a 27% increase compared to the previous year. The company's focus on restructuring has led to a significant reduction in net losses, with an adjusted EBITDA increase from $(117) million in the prior year to $(47) million. Ginkgo secured a $29 million contract from ARPA-H to innovate in essential medicine manufacturing, while maintaining a goal of achieving $250 million in cost reductions by September 2025. The company continues to navigate a complex operational landscape amidst its ongoing restructuring.
Read more →-DNA
Feb 25, 2025Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site con
Ginkgo Bioworks reported its financial results for the fourth quarter and full year 2024, showcasing a 29% growth in Cell Engineering revenue over 2023. While total revenue decreased by 10% for the year primarily due to changes in Biosecurity revenue, the company achieved significant cash flow improvements and reduced GAAP net losses. Ginkgo remains optimistic about its restructuring efforts and projections for 2025 revenue in both Cell Engineering and Biosecurity segments.
Read more →-DNA
Nov 12, 2024Ginkgo Bioworks Reports Third Quarter 2024 Financial Results Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkg
Ginkgo Bioworks reported its third quarter financial results, revealing a 61% increase in total revenue to $89 million, primarily due to a non-cash revenue release. However, revenue excluding this item decreased by 21%, with significant drops noted in cell engineering. The company has made strides in securing new contracts with major pharmaceutical players and is implementing substantial cost-cutting measures. Ginkgo is also on track to reach adjusted EBITDA breakeven by the end of 2026 amid ongoing restructuring efforts.
Read more →-DNA
Aug 8, 2024Ginkgo Bioworks Reports Second Quarter 2024 Financial Results Ginkgo provides update on its restructuring process including estimated annualized cost savings of over $85 million from reduction in force
Ginkgo Bioworks reported its second quarter financial results for 2024, revealing a 30% decrease in total revenue to $56 million compared to the previous year. The company's loss from operations rose to $(223) million, reflecting the costs associated with restructuring and workforce reduction. Despite the downturn, Ginkgo announced strategies aimed at reaching adjusted EBITDA breakeven by the end of 2026 and highlighted initial success with its new Lab Data as a Service offering. The company expects to save over $85 million annually from the recent cuts and plans to continue focusing on operational efficiency.
Read more →-DNA
May 13, 2024▲ +10.5%on this news
Ginkgo Bioworks Receives Continued Listing Standard Notice From NYSE Ginkgo's Class A Common Stock continues to trade on the
Ginkgo Bioworks Holdings, Inc. has received a notice from the NYSE indicating it is not in compliance with listing standards due to its Class A common stock trading below $1 for a consecutive 30-day period. While this notice does not lead to immediate delisting, the company has a six-month window to regain compliance. Ginkgo intends to address this issue and continue its trading on the NYSE. The company has stated that its business operations remain unaffected by this notice.
Read more →-DNA
May 9, 2024Ginkgo Bioworks Reports First Quarter 2024 Financial Results Ginkgo announces several initiatives to accelerate path to Adjusted EBITDA breakeven by end of 2026 Initiatives include a reduction of $200 million in annualiz
Ginkgo Bioworks reported its first quarter financial results for 2024, revealing a 53% drop in total revenue to $38 million, primarily due to the reduction of K-12 testing within its Biosecurity segment. The company is implementing a $200 million reduction in annual operating expenses by mid-2025 to steer toward adjusted EBITDA breakeven by the end of 2026. Despite the negative revenue trajectory, Ginkgo highlighted initiatives such as new partnerships and the introduction of Lab Data as a Service to drive growth. The company also continues to hold a strong cash position with $840 million in liquidity, providing a buffer for its transformation efforts.
Read more →-DNA
Feb 29, 2024Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results $251 million of Total revenue in 2023 $139 million in Cell Engineering services revenue, representing 31% growth over 2022 78 new Cell Programs
Ginkgo Bioworks reported its fourth quarter and full year 2023 financial results, showing a total revenue of $251 million, despite a significant decline from 2022. The company highlighted a 31% growth in Cell Engineering services and added 78 new Cell Programs, indicating positive momentum in the biopharma sector. However, there was a notable 65% drop in fourth quarter revenue primarily due to a reduction in K-12 testing and decreased downstream value share. With a year-end cash balance of nearly $950 million, Ginkgo is positioned to pursue its strategic objectives amid ongoing operational losses.
Read more →-DNA
Jan 10, 2024▼ -6.6%on this news· ran to -19% by day 3
Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference Expects to meet 2023 new program and revenue guidance ranges Ended the year with nearly $950 million in cash and cash equivalents, a strong b
Ginkgo Bioworks recently provided business updates at the J.P. Morgan Healthcare Conference, projecting that it will meet its 2023 guidance for new programs and revenue. The company reported a robust performance with significant growth in revenue attributed to biopharma customers, which increased by over 50% this past year. Ginkgo's strong financial position, ending 2023 with nearly $950 million in cash, is expected to support strategic opportunities in the market. Key highlights included the continuation of partnerships with pharmaceutical giants and an anticipation of additional growth as the company plans for 2024.
Read more →-DNA
Nov 8, 2023Ginkgo Bioworks Reports Third Quarter 2023 Financial Results Ginkgo added 21 new Cell Programs to the Foundry platform in Q3 2023 Entered into strategic cloud and AI partnership with Google Cloud first milestone recently
Ginkgo Bioworks announced its Q3 2023 results, highlighting the addition of 21 new Cell Programs to its Foundry platform and a strategic partnership with Google Cloud. The company also entered a collaboration with Pfizer for RNA drug discovery, potentially worth $331 million. Despite a decrease in total revenue by 17% year-over-year, Ginkgo reported a strong cash position exceeding $1 billion. The financial results reflect ongoing challenges in its Biosecurity segment but show growth in Cell Engineering revenue.
Read more →-DNA
Aug 29, 2023▲ +24%on this news
Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity • Ginkgo and Google Cloud enter strategic five-year cloud and AI partnership • Ginkgo
Ginkgo Bioworks has partnered with Google Cloud in a strategic five-year initiative aimed at advancing AI technology for biological engineering and biosecurity. This collaboration will utilize Google Cloud's Vertex AI platform to develop innovative large language models that will support a range of applications in genomics and protein engineering. As part of the partnership, Google Cloud will provide funding to assist Ginkgo in achieving its goals, emphasizing the critical role this relationship may play in transforming the biotechnology landscape. Ginkgo plans to integrate new AI tools with its existing data resources, enhancing both efficiency and discovery in scientific research.
Read more →-DNA
Aug 23, 2023▲ +7.8%on this news
to Ginkgo s Current Report on Form 8-K filed with the SEC on
Ginkgo Bioworks has filed an 8-K report regarding the completion of its acquisition of Zymergen. The unaudited pro forma condensed combined financial information reflects the merger's impact on Ginkgo's financials for the year ended December 31, 2022. This report outlines the historical performance and adjustments made to account for the merger, indicating potential operational challenges and a preliminary financial outlook for the combined entity. The final accounting for the merger will be established within a year, considering new assessments and adjustments.
Read more →-DNA
Aug 9, 2023Ginkgo Bioworks Reports Second Quarter 2023 Financial Results Ginkgo added 21 new Cell Programs to the Foundry platform in Q2 2023 Highlighted continued success selling into large established biotech R&D organizations wi
Ginkgo Bioworks has reported its financial results for Q2 2023, highlighting the addition of 21 new Cell Programs to its Foundry platform, marking a significant growth of 62% year-over-year. The company ended the quarter with approximately $1.1 billion in cash, which positions it strongly for future development. Despite these positive developments, Ginkgo experienced a 44% decline in total revenue, primarily due to the expected decrease in K-12 testing in its Biosecurity segment. Additionally, the company reported significant operational losses, but its Cell Engineering revenue showed resilience with a 72% increase year-on-year.
Read more →Competitive Position
How DNA ranks across every disease it competes inCompetitive Position is a premium feature
See how DNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial